Archive: February 03 2021


Onclive11

Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refract...

The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.

Visit website